|
|
||||||||
RESEARCH AND PRACTICE |
Grace E. Macalino is with the Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Boston, Mass. Darpun Dhawan is with Brown Medical School, Providence, RI. Josiah D. Rich is with the Department of Medicine and Community Health, Brown University and the Center for Prisoner Health and Human Rights at The Miriam Hospital, Providence, RI.
Correspondence: Requests for reprints should be sent to Grace E. Macalino, PhD, Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, 750 Washington St, Box 63, Boston, MA 02111 (e-mail: gmacalino{at}tufts-nemc.org).
| ABSTRACT |
|---|
|
|
|---|
In 2003, the Centers for Disease Control and Prevention issued recommendations to screen all inmates with a history of injection drug use or other risk factors for hepatitis C. We compared self-reported risk factors for hepatitis C with serostatus from inmates in the Rhode Island Department of Corrections. Of the male inmates who were hepatitis C positive, 66% did not report injection drug use. Risk-based testing underestimates the hepatitis C virus (HCV) prevalence in correctional settings and limits the opportunity to diagnose and prevent hepatitis C infection.
| INTRODUCTION |
|---|
|
|
|---|
Policymakers, researchers, and the public continue to debate the need to screen asymptomatic HCV infection and the adequacy of screening on the basis of risk factors.35 We compared self-reported injection drug use with actual serostatus among inmates to evaluate the validity of self-reports in this setting. These data can inform whether testing on the basis of self-report will impact HCV infection among prisoners.
| METHODS |
|---|
|
|
|---|
For this analysis, we compared hepatitis C blood test results with injection drug use, self-reported to a nurse during intake in response to a question about either "drug or alcohol abuse" or "IV drug use." Because this was a blinded research survey, no additional education was given regarding HCV infection beyond informed consent. Each sentenced inmate was counted once, despite potential multiple incarcerations during the 2-year study period.
| RESULTS |
|---|
|
|
|---|
Our data comparing laboratory test results and self-reported data are shown in Table 1
. Of those who were found to be hepatitis C positive, 65.5% of the men and 44.2% of the women did not report injection drug use at intake. Women were 2.3 times more likely (95% CI = 1.7, 3.0) to report injection drug use among inmates who were HCV positive than were men.
|
| DISCUSSION |
|---|
|
|
|---|
The fact that women were more likely to report injection drug use may reflect gender disparities between these particular correctional facilities. The womens correctional facility processes 6 times fewer intakes per day, and all female inmates are seen by 1 physician. The intimate environment of the womens prison may allow for greater trust and disclosure of drug use.
As in many other correctional facilities, prisoners in the Rhode Island Department of Corrections may request testing, but there is no systematic access to information about HCV transmission, the availability of testing, or risk reduction practices.5 Because most of the individuals are asymptomatic, if they are identified earlier, they can be educated to abstain from alcohol, seek treatment before the development of symptoms, and prevent transmission to others.5 Because 1.3 million individuals who are infected with HCV are released from prison annually,11 these efforts would affect not only the incarcerated population but also the community at large.
Concerns about mandatory testing in the correctional setting are validincluding topics such as confidentiality, stigma, cost, and adequate follow-up. However, testing only those with reported risk behaviors reinforces the stigma of HCV infection and drug use that may have led to incarceration and serves to further marginalize these individuals. The Rhode Island model of mandatory HCV testing has shown that early identification of infected individuals can lead to adequate education and clinical care that can begin during incarceration and continue into the community.12 Although no formal studies have been completed to date, the cost saved by early HCV diagnosis must be considered from both a clinical standpoint and the goal of averting new infections.
Critical evaluation and creative solutions are needed to overcome the challenges of HCV testing in unique correctional subpopulations (e.g., short stay, women). These solutions should include strategies that are responsive to the needs of a particular correctional setting, such as routine, mandatory, or voluntary HCV testing at intake, in addition to universal access to education and counseling services. Our data support the argument that risk-based screening alone is not sufficient to accurately confront the magnitude of HCV infection in prisons. Screening, diagnosis, and prevention services must be incorporated into correctional health systems to reduce progression of clinical disease and stem the transmission of infection.
| Acknowledgments |
|---|
The authors acknowledge all the Rhode Island Prison Study staff, whose endless hours of work and support contributed in so many waysin particular Michael Patterson for his laboratory expertise and Michelle McKenzie for overseeing the project.
Human Participant Protection
All procedures and human participant protections related to this study were approved by the local institutional review boards of the Miriam Hospital, the Johns Hopkins Bloomberg School of Public Health, and the Centers for Disease Control and Prevention.
| Footnotes |
|---|
Contributors
G. E. Macalino originated the study, supervised all aspects of its implementation, and led the writing of the brief. D. Dhawan assisted with the analyses, conceptualization, and writing of the brief. J. D. Rich established links between the study and the Rhode Island prison and provided senior guidance while writing the brief.
Accepted for publication April 1, 2005.
| References |
|---|
|
|
|---|
2. Weinbaum C, Lyerla R, Margolis HS. Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention [published erratum appears in MMWR Recomm Rep. 2003;52:205214]. MMWR Recomm Rep. 2003;52(RR-1):136; quiz CE14.[Medline]
3. Butterfield F. Infections in newly released inmates are a rising concern. New York Times. January 28, 2003;sect A1:14.
4. Hammett TM. Adopting more systematic approaches to hepatitis C treatment in correctional facilities. Ann Intern Med. 2003;138:235236.
5. Alter MJ, Seeff LB, Bacon BR, et al. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med. 2004;141:715717.
6. Macalino GE, Vlahov D, Sanford-Colby S, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health. 2004;94:12181223.
7. Harrison L, Hughes A. Introductionthe validity of self-reported drug use: improving the accuracy of survey estimates. NIDA Res Monogr. 1997;167:116.
8. Hser YI. Self-reported drug use: results of selected empirical investigations of validity. NIDA Res Monogr. 1997;167:320343.[Medline]
9. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998;51:253263; discussion 267268.[CrossRef][ISI][Medline]
10. Fendrich M, Xu Y. The validity of drug use reports from juvenile arrestees. Int J Addict. 1994;29:971985.[ISI][Medline]
11. The Health Status of Soon-to-Be Released Inmates: A Report to Congress. Chicago, Ill: National Commission on Correctional Health Care; 2002.
12. Crosland C, Poshkus M, Rich JD. Treating prisoners with HIV/AIDS: the importance of early identification, effective treatment, and community follow-up. AIDS Clin Care. 2002;14:6771, 76.
This article has been cited by other articles:
![]() |
M F Vescio, B Longo, S Babudieri, G Starnini, S Carbonara, G Rezza, and R Monarca Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis J Epidemiol Community Health, April 1, 2008; 62(4): 305 - 313. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |